MX2022002723A - Receptores de antigeno dimerico (dar) que se enlazan a bcma. - Google Patents

Receptores de antigeno dimerico (dar) que se enlazan a bcma.

Info

Publication number
MX2022002723A
MX2022002723A MX2022002723A MX2022002723A MX2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A MX 2022002723 A MX2022002723 A MX 2022002723A
Authority
MX
Mexico
Prior art keywords
antigen receptors
dar
dimeric
dimeric antigen
antigen
Prior art date
Application number
MX2022002723A
Other languages
English (en)
Inventor
Gunnar F Kaufmann
Henry Hongjun Ji
Wenzhong Guo
Yanliang Zhang
Bei Bei Ding
Original Assignee
Sorrento Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorrento Therapeutics Inc filed Critical Sorrento Therapeutics Inc
Publication of MX2022002723A publication Critical patent/MX2022002723A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona construcciones de los receptores de los antígenos diméricos (DAR, por sus siglas en inglés) que se enlazan a un antígeno blanco de BCMA, en donde la construcción de DAR comprende una región de enlace de la cadena pesada en una cadena de polipéptido y una región de enlace de la cadena ligera en una cadena de polipéptido separada. Las dos cadenas de polipéptidos que componen los receptores de los antígenos diméricos se pueden dimerizar para formar un dominio de enlace al antígeno. Los receptores de los antígenos diméricos tienen propiedades similares a las de los anticuerpos, debido a que se enlazan de una forma específica a un antígeno blanco. Los receptores de los antígenos diméricos se pueden utilizar para la terapia celular dirigida.
MX2022002723A 2019-09-05 2020-09-04 Receptores de antigeno dimerico (dar) que se enlazan a bcma. MX2022002723A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US202063030145P 2020-05-26 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (1)

Publication Number Publication Date
MX2022002723A true MX2022002723A (es) 2022-03-22

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022002723A MX2022002723A (es) 2019-09-05 2020-09-04 Receptores de antigeno dimerico (dar) que se enlazan a bcma.

Country Status (10)

Country Link
US (1) US20220251168A1 (es)
EP (1) EP4025227A4 (es)
JP (1) JP2022546577A (es)
KR (1) KR20220057598A (es)
CN (1) CN114650829A (es)
AU (1) AU2020341712A1 (es)
CA (1) CA3149867A1 (es)
IL (1) IL291076A (es)
MX (1) MX2022002723A (es)
WO (1) WO2021046445A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021016791A2 (pt) * 2019-02-26 2021-11-16 Sorrento Therapeutics Inc Proteínas de ligação de antígenos que se ligam a bcma
US20230167191A1 (en) 2020-04-24 2023-06-01 Sorrento Therapeutics, Inc. Memory Dimeric Antigen Receptors (mDARs)
TW202328192A (zh) * 2021-09-06 2023-07-16 荷蘭商珍美寶公司 能結合ｃｄ２７之抗體、彼之變異體及彼等之用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170051037A1 (en) * 2014-05-02 2017-02-23 Cellectis Cs1 specific multi-chain chimeric antigen receptor
CA2986030A1 (en) * 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
IL258405B (en) * 2015-10-23 2022-09-01 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric structures and their uses
WO2018237192A1 (en) * 2017-06-21 2018-12-27 Gsbio, Llc BISPECIFIC ANTIBODIES HETERODIMERS
WO2019173837A1 (en) * 2018-03-09 2019-09-12 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dar)
BR112021016791A2 (pt) * 2019-02-26 2021-11-16 Sorrento Therapeutics Inc Proteínas de ligação de antígenos que se ligam a bcma

Also Published As

Publication number Publication date
JP2022546577A (ja) 2022-11-04
EP4025227A1 (en) 2022-07-13
IL291076A (en) 2022-05-01
KR20220057598A (ko) 2022-05-09
CA3149867A1 (en) 2021-03-11
AU2020341712A1 (en) 2022-03-31
EP4025227A4 (en) 2023-11-01
US20220251168A1 (en) 2022-08-11
WO2021046445A1 (en) 2021-03-11
CN114650829A (zh) 2022-06-21

Similar Documents

Publication Publication Date Title
MX2022002723A (es) Receptores de antigeno dimerico (dar) que se enlazan a bcma.
CY1120849T1 (el) Αντισωμα που συνδεεται σε ανθρωπινο cd3
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
MX2021015518A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2021009151A (es) Anticuerpos y receptores de antigeno quimerico especificos para ror1.
MX2022006527A (es) Construcciones polipeptidicas de union al antigeno modificadas y usos de estas.
MX2018007630A (es) Anticuerpos contra la metaloproteinasa de matriz 9.
EP4219559A3 (en) Antibodies for lilrb2
PE20190108A1 (es) Moleculas de anticuerpo para el tratamiento del cancer
PE20241349A1 (es) Anticuerpos de union a cd3
WO2019089969A3 (en) Antibodies and chimeric antigen receptors specific for b-cell maturation antigen
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
CO6761352A2 (es) Anticuerpos neutralizadores anti-ccl20
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
AR083747A1 (es) Anticuerpos anti-il-23
PH12014501931A1 (en) Antibodies to matrix metalloproteinase 9
MY172718A (en) Humanized universal light chain mice
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
PH12015501505A1 (en) Antibodies that bind to tl1a and their uses
EP4218409A3 (en) Mice expressing a limited immunoglobulin light chain repertoire
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
MX2021005048A (es) Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos.
MX2022009915A (es) Anticuerpos anti-ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos.
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.